Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-11-2010 | Original Paper

Feasibility of ¹²⁵I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma

Authors: Chuanxing Li, Fujun Zhang, Weidong Zhang, Liang Zhang, Zilin Huang, Peihong Wu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2010

Abstract

Purpose

To evaluate ¹²⁵I seed brachytherapy combined with sorafenib in the treatment of patients with multiple lung metastases after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC).

Patients and methods

From July 2006 to December 2009, eight patients with multiple lung metastases after OLT for HCC underwent ¹²⁵I brachytherapy combined with sorafenib, and laboratory and radiologic examinations were performed before and after the treatment. Changes in symptoms and survival time were noted at follow-up.

Results

The follow-up time ranged from 14 to 37 months. The local control rates of multiple lung metastases after OLT for HCC after 4, 6, 12, 18 and 24 months were 92.2, 82.4, 76.2, 73.3 and 72.2%, respectively. Four patients died (survival time 14, 15, 25 and 37 months, respectively), and four patients are alive at the time of this writing (follow-up time 18, 21, 26 and 30 months, respectively). The overall 1-, 2- and 3-year survival rates were 100, 50 and 12.5%, respectively. The median survival time was 21 months. Procedure-related complications were minimal.

Conclusion

¹²⁵I brachytherapy combined with sorafenib is safe, feasible and promising approach in the treatment of patients with multiple lung metastases after OLT for HCC, but large-scale randomized clinical trials are necessary for confirmation.

Blasko JC, John TM, Peter S et al (2002) Brachytherapy for carcinoma of the prostate: techniques, patients selection and clinical outcome. Semi Radiat Oncol 12:81–84CrossRef

Calvisi DF, Ladu S, Gorden A et al (2006) Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130:1117–1128CrossRefPubMed

Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59:561–574CrossRefPubMed

Chen Z, He F, Zeng F et al (2006) Impact of steroid withdrawal on recurrent rate of carcinoma after liver transplantation of hepatocellular carcinoma. Chin J Organ Transpl 27:156–159

Deuffic S, Poynard T, Buffat L et al (1998) Trends in primary liver cancer. Lancet 351:214–215CrossRefPubMed

El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750CrossRefPubMed

Ito Y, Sasaki Y, Horimoto M et al (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27:951–958CrossRefPubMed

Klintmalm GB (2004) The history of organ transplantation in the Baylor Health Care System. Proc (Bayl Univ Med Cent) 17:23–34

Lee HH, Joh JW, Park JH et al (2005) Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma. Transplant Proc 37:1251–1253CrossRefPubMed

Leslie TA, Kennedy JE, Illing RO et al (2008) High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response. Br J Radiol 81:564–571CrossRefPubMed

Li Z (2000) Experimental measurements of dosimetric parameters on the transverse axis of a new ¹²⁵I source. Med Phys 27:1275–1280CrossRefPubMed

Ling CC (1992) Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23:81–87PubMed

Little SA, Fong Y (2001) Hepatocellular carcinoma: current surgical management. Semin Oncol 28:474–486CrossRefPubMed

Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858CrossRefPubMed

Llovet JM, Ricci S, Mazzaferro V et al (2007) Sorafenib improves survival in advanced hepatocellular carcinoma: results of a phase III randomized placebocontrolled trial. J Clin Oncol 25:LBA1

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed

Markus U, Ulrich S, Gabriele K et al (2006) Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol 36:1306–1311CrossRef

Mazeron JJ, Noel G, Simon JM (2002) Head and neck brachytherapy. Semi Raidat Oncol 12:95–108CrossRef

Mazzaferro V, Regalia E, Doci R et al (1996a) Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMed

Mazzaferro V, Regalia E, Doci R et al (1996b) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMed

Perez Saborido B, Loinaz Segurola C, Gimeno Calvo A et al (2003) Liver transplantation for hepatocellular carcinoma: our experience from 1986. Transplant Proc 35:1825–1826CrossRefPubMed

Pokorny H, Gnant M, Rasoul-Rockenschaub S et al (2005) Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 5:788–794CrossRefPubMed

Poon RT, Fan ST, Lo CM et al (2002) Long term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373–382CrossRefPubMed

Ravaioli M, Grazi GL, Ercolani G et al (2004) Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 78:1780–1786CrossRefPubMed

Schlitt HJ, Neipp M, Weimann A et al (1999) Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Onco 17:324

Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41:864–880CrossRefPubMed

Shao ZX, Xu X, Zheng SS et al (2006) Serum α-fetoprotein alterations and tumor recurrence after liver transplantation for hepatocellular carcinoma patients. Chin J of Gen Surg 21:351–353

Sharma P, Balan V, Hernandez JL et al (2004) Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 10:36–41CrossRefPubMed

Taylor-Robinson SD, Foster GR, Arora S et al (1997) Increase in primary liver cancer in the UK. Lancet 350:1142–1143CrossRefPubMed

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

Villanueva A, Newell P, Chiang DY et al (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76CrossRefPubMed

Vivarelli M, Bellusci R, Cucchetti A et al (2002) Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74:1746–1751CrossRefPubMed

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed

Yao FY, Ferrell L, Bass NM et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394–1403CrossRefPubMed

Zheng SS, Xu X, Liang TB et al (2005) Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 case. Chin J Surg 43:450–453PubMed

Title: Feasibility of 125I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma
Authors: Chuanxing Li
Fujun Zhang
Weidong Zhang
Liang Zhang
Zilin Huang
Peihong Wu
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0821-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Feasibility of ¹²⁵I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma

Abstract

Purpose

Patients and methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2010

Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer

Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome

Clinical investigation of malignant mesothelioma in Japan

PI3K/Akt and GSK-3β prevents in a differential fashion the malignant phenotype of colorectal cancer cells

Beta2-GPI: a novel factor in the development of hepatocellular carcinoma

Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page